… , patients with diabetes experience increased cardiovascular (CV) events correlated with …
arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) 1 trial due to increased …

… Here we review how GLP-1 and clinically approved GLP-1R agonists engage … cardiovascular
disease. We discuss how GLP-1R agonists modify inflammation, cardiovascular physiology…

… for GLP-1 in response to nutrients, the expression of GLP-1 receptor in various tissues and
the direct and indirect cardiovascular actions of GLP-1. GLP-1's action in the central nervous …

… nor decreased cardiovascular events. Here we review the cardiovascular actions of GLP-1R …
of the potential mechanisms that underlie the cardiovascular benefit and safety of these …

… glucose-lowering actions, GLP-1 may also exert several beneficial actions on the cardiovascular
system. This review will discuss the emerging cardiovascular actions of GLP-1 and its …

… peptide-1 receptor agonists represent a novel class of anti-hyperglycemic agents that have a
cardiac… the multifactorial cardiovascular effects of glucagon-like peptide-1 receptor agonists …

… a broad range of overlapping and unique cardiovascular actions. Native GLP-1 regulates
cardiovascular biology via activation of the classical GLP-1R, or through GLP-1(9–36), a …

… Glucagon-like peptide 1 (GLP-1) is an incretin hormone responsible for amplification of
insulin secretion when nutrients are given orally, as opposed to intravenously, and it retains its …

… action for GLP1R agonist-mediated cardioprotection, which could have therapeutic potential
in a range of cardiovascular … preserving the beneficial cardiovascular actions of structurally …

… of a given peptide hormone may vary among target cells. This review summarizes the present
knowledge about the action of PTH and PTH-rP on cardiovascular target cells with a focus …